ExpreS2ion Biotech Holding AB (publ) (EXPRS2) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to today's event where we have the pleasure to present expression biotechnology. To help us through today's presentation, we are joined by CEO Ben Fransen and CFO Keith Alexander. The topic, of course, you could see a report this morning, but I think more abroad, a very large news flow coming in the course on a lot of other than the financials as always ask questions in the box down below i'm speaking fast we have a firm deadline at 11 30 we will try and catch as many questions as possible but uh you will have joined a lot of events presentations here in in the coming days so i think people will have a good way a good possibility to ask questions later on but for now i have the call over to you bent thank you very much michael Good morning, everybody, and welcome to Expressions' third quarter webcast. I'm Ben Fransen, CEO of Expressions Biotechnologies, and with me today is our CFO, Keith Alexander. We'll take you through our progress this quarter, how we are advancing our HER2 breast cancer immunotherapy, expanding on global vaccine partnerships, and keeping track on our financial position. We'll start with strategy and pipeline updates, focusing on clinical progress, collaborations and upcoming catalysts. And then Kies will walk you through the financials before we open for questions. This quarter has been about driving momentum across both pillars of our business. First, our proprietary HER2 cancer vaccine and second, our global vaccine collaborations. Together, these create a unique balance between high impact innovation and revenue generating partnerships. Our strategy continues to be driven by these four key pillars. From top left, we are advancing our proprietary pipeline led by our HER2 breast cancer vaccine, ES2B-C001. We're intensifying global vacci...